Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tc 99m tilmanocept - Navidea Biopharmaceuticals

Drug Profile

Tc 99m tilmanocept - Navidea Biopharmaceuticals

Alternative Names: Lymphoaim; Lymphoseek; NEO3-09; Tc 99m-diethylenetriamine pentaacetic acid mannosyl dextran; Tc 99m-DTPA-mannosyl dextran; Tc99m tilmanocept; Technetium Tc 99m tilmanocept; Tilmanocept

Latest Information Update: 20 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California, San Diego
  • Developer Maimonides Medical Center; National Cancer Institute (USA); National Institute of Health Clinical Center; Navidea Biopharmaceuticals; Norgine; University of California, San Diego
  • Class Heavy metals; Imaging agents; Radiopharmaceutical diagnostics; Technetium compounds
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Head and neck cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
  • Phase III Cardiovascular disorders; Rheumatoid arthritis
  • Phase II Cervical cancer; Kaposi's sarcoma
  • Clinical Phase Unknown Mouth neoplasm
  • No development reported Colorectal cancer; Crohn's disease; Endometrial cancer; Liver metastases; Non-alcoholic steatohepatitis

Most Recent Events

  • 14 Jun 2023 Navidea Biopharmaceuticals entered into an amendment with Cardinal Health
  • 10 Nov 2022 Efficacy data from a phase II trial in Rheumatoid arthritis presented at the ACR Convergence (ACR-2022)
  • 15 Sep 2022 Efficacy data from a phase-II trial in Rheumatoid arthritis released by Navidea Biopharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top